Xencor, Inc. ( XNCR ) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 May 5, 2026 8:00 AM EDT

Company Participants

Charles Liles - Associate Director and Head of Corporate Communications & Investor Relations

Bassil Dahiyat - Co-Founder, CEO, President & Director

John Desjarlais - Executive VP of Research & Chief Scientific Officer

Mark Osterman - Senior Vice President of Clinical Development (Autoimmune)

Dane Leone - Executive VP & Chief Strategy Officer

Conference Call Participants

Vipul Jairath

Albert Agustinus - Leerink Partners LLC, Research Division

Ikenna Okafor - TD Cowen, Research Division

Etzer Darout - Barclays Bank PLC, Research Division

Timur Ivannikov - Cantor Fitzgerald & Co., Research Division

Sean McCutcheon - Raymond James & Associates, Inc., Research Division

Gregory Renza - Truist Securities, Inc., Research Division

Madeleine Stone - William Blair & Company L.L.C., Research Division

Eva Fortea-Verdejo - Wells Fargo Securities, LLC, Research…